Kejing Zhu

Kejing Zhu

Auto-generated profile, based on publicly available information

Kejing Zhu

Organ Transplantation Department, The Affiliated Hospital of Guizhou Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Journal of Analytical Methods in Chemistry
Verified
Journal Article
Open access
PDF file
KZKejing Zhu
Kejing Zhu
SZShengsheng Zhang
Shengsheng Zhang
KYKeyu Yue
Keyu Yue
YZYaming Zuo
Yaming Zuo
YNYulin Niu
Yulin Niu
WPWei Pan
Wei Pan
Proline is an important amino acid that widely affects life activities. It plays an important role in the occurrence and development of diseases. It is of great significance to monitor the metabolism of the machine. With the great advantages of deep learning in feature extraction, near‐infrared analysis technology has great potential and has been widely used in various fields. This study explored the potential application of near‐infrared spectroscopy in the detection of serum proline. We collected blood samples from clinical sources, separated the serum, established a quantitative model, and determined the changes in proline. Four algorithms of SMLR, PLS, iPLS, and SA were used to model proline in serum. The root mean square errors of prediction were 0.00111, 0.00150, 0.000770, and 0.000449, and the correlation coefficients (Rp) were 0.84, 0.67, 0.91, and 0.97, respectively. The experimental results show that the model is relatively robust and has certain guiding significance for the clinical monitoring of proline. This method is expected to replace the current mainstream but time‐consuming HPLC, or it can be applied to rapid online monitoring at the bedside.

1 January 2023 in International Journal of Intelligent Systems
Verified
Journal Article
Open access
PDF file
KZKejing Zhu
Kejing Zhu
JSJie Shen
Jie Shen
WXWen Xu
Wen Xu
KYKeyu Yue
Keyu Yue
LZLiying Zhu
Liying Zhu
WPWei Pan
Wei Pan
Cancer is an increasing burden on global health. Breast and lung cancers are the two tumors with the highest incidence rates. The study shows that early detection and early diagnosis are important prognostic factors for breast and lung cancers. Due to the great advantages of artificial intelligence in feature extraction, the combination of infrared analysis technology may have great potential in clinical applications. This study explores the potential application of mid‐infrared spectroscopy combined with machine learning for the differentiation of breast and lung cancers. The experiment collects blood samples from clinical sources, separates serum, trains classification models, and finally predicts unknown sample categories. We use k‐fold cross‐validation to determine the training set of 301 cases and the test set of 50 cases. Through differential spectrum analysis, we found that the intervals of 1318.59–1401.03 cm−1, 1492.15–1583.27 cm−1, and 1597.25–1721.64 cm−1 have significant differences, which may reflect the absorption of key chemical bonds in protein molecules. We use a total of 24 models such as decision trees, discriminant analysis, support vector machines, and K‐nearest neighbor to train, identify, and distinguish spectra. The results show that under the same conditions, the prediction model trained based on fine KNN has the best performance and can perform 100% prediction on the test set samples. This also shows that our model has important potential for auxiliary diagnosis of serum breast cancer and lung cancer. This method may help to further achieve comprehensive screening of associated cancers in underserved areas, thereby reducing the cancer burden through early detection of cancer and appropriate treatment and care of cancer patients.

21 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QYQizhen Yang
Qizhen Yang
STShuai Tang
Shuai Tang
KZKejing Zhu
Kejing Zhu
YNYulin Niu
Yulin Niu
Background: Kidney transplantation (KT) improves survival in end-stage renal disease, but long-term outcomes are undermined by antibody-mediated rejection (ABMR) and metabolic complications. Recent insights suggest a mechanistic interplay between immune injury and metabolic dysregulation. Methods: This narrative review synthesizes current literature on the pathogenesis and clinical impact of antibody-mediated rejection (ABMR), the epidemiology of post-transplant metabolic syndrome—including post-transplant diabetes mellitus, dyslipidemia, and hypertension—and their bidirectional relationship. Emerging diagnostic tools and therapeutic strategies are also examined. Results: ABMR remains a leading cause of late graft failure. Concurrently, 30% ~ 50% of KT recipients develop metabolic syndromes within the first year, driven by immunosuppressive agents and underlying risk factors. Metabolic abnormalities enhance endothelial activation and complement-driven inflammation, aggravating ABMR. Conversely, immunosuppressive intensification to treat ABMR worsens metabolic profiles, forming a vicious cycle. Novel immunologic (e.g., complement inhibitors, anti-CD38 antibodies) and metabolic (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) agents show promise, though data on long-term efficacy remain limited. Conclusion: Integrated immunometabolic strategies are essential for optimizing graft and patient survival. Future research should focus on personalizing immunosuppression and targeting metabolic health to break the feedback loop linking ABMR and metabolic disease.

11 September 2024
Verified
Book Chapter
Open access
PDF file
LCLuobei Chen
Luobei Chen
KZKejing Zhu
Kejing Zhu
Cancer is currently the leading cause of death in countries and an important obstacle to extending national life expectancy. Due to the delayed reporting of results and the delay of patient care caused by the current medical workflow, the result will affect the treatment and prognosis of patients and bring potential economic burden to medical institutions. The development of novel, low-cost, and rapid diagnostic platforms is the key to breaking through the current diagnosis and treatment dilemma. The potential of infrared (IR) spectroscopy as a powerful clinical tool is very clear, as can be seen from countless proof-of-principle studies with high specificity and sensitivity for disease detection and classification. Therefore, for cancer screening, rapid detection, simple operation, low cost, and alternative or auxiliary diagnostic technology infrared spectroscopy has important potential.